NADAC acquisition cost data for BALZIVA 28 TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00555903458 | $0.4341 | 2022-12-21 | Rx |
| 00555903479 | $0.4341 | 2022-12-21 | Rx |
| 00555903458 | $0.4341 | 2022-12-21 | Rx |
| 00555903479 | $0.4341 | 2022-12-21 | Rx |
Generic: Norethindrone-Ethin. Estradiol | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $68.7K | 1,819 | 335 | $0.8326 |
| 2020 | $69.3K | 1,529 | 286 | $0.8899 |
| 2021 | $68.7K | 1,472 | 317 | $0.8743 |
| 2022 | $55.4K | 1,220 | 251 | $0.8377 |
| 2023 | $52.4K | 1,115 | 242 | $0.8164 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $3.7K | 84 | 21 |
| Pennsylvania | $3.6K | 93 | 15 |
| North Carolina | $2.9K | 46 | 11 |
| Illinois | $2.8K | 51 | N/A |
| Texas | $2.6K | 51 | N/A |
| Maryland | $2.6K | 54 | 11 |
| Connecticut | $2.5K | 44 | N/A |
| South Carolina | $2.4K | 53 | 13 |
| Ohio | $2.2K | 33 | 11 |
| Indiana | $2.2K | 52 | N/A |
| Missouri | $1.7K | 38 | N/A |
| Louisiana | $1.7K | 46 | N/A |
| Alabama | $1.7K | 27 | N/A |
| Virginia | $1.6K | 18 | N/A |
| Michigan | $1.6K | 27 | N/A |
| Utah | $1.6K | 30 | N/A |
| Kentucky | $1.5K | 30 | N/A |
| Tennessee | $1.2K | 23 | N/A |
| California | $1.2K | 53 | N/A |
| Nebraska | $1.1K | 34 | N/A |
| New Jersey | $995.19 | 30 | N/A |
| Maine | $889.54 | 28 | N/A |
| Georgia | $885.46 | 22 | N/A |
| Oklahoma | $882.65 | 17 | N/A |
| West Virginia | $816.53 | 16 | N/A |
| Florida | $788.82 | 15 | N/A |
| Massachusetts | $713.27 | 14 | N/A |
| Arkansas | $421.99 | 13 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.